References
- 1. Ardalan M, Rezaeifar P. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy: first report from Iran. Nephrourol Mon. 2014;6(6):e18900.10.5812/numonthly.18900433066725738110
- 2. Polito MG, Kirsztajn GM. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome. J Bras Nefrol. 2010;32(3):303-315.
- 3. Agosti P, Mancini I, Artoni A, et al. The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age. Thromb Res. 2020;187:197-201. doi:10.1016/j.thromres.2019.10.010.10.1016/j.thromres.2019.10.01031685248
- 4. Stanley M, Michalski JM. Thrombotic Thrombocytopenic Purpura (TTP). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
- 5. Nuñez Zuno JA, Khaddour K. Thrombotic Thrombocytopenic Purpura Evaluation and Management. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
- 6. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335.10.1111/j.1365-2141.2012.09167.x22624596
- 7. Mariotte E, Veyradier A. Thrombotic thrombocytopenic purpura: from diagnosis to therapy. Curr Opin Crit Care. 2015;21(6):593-601.10.1097/MCC.000000000000025526418759
- 8. Pandey MR, Vachhani P, Ontiveros EP. Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib. Case Rep Hematol. 2017;2017:9681832.10.1155/2017/9681832535845128367342
- 9. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014;29(3):148-167.10.1002/jca.2130224136342
- 10. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4):E153-E159.10.1503/cmaj.160142526656927754896
- 11. Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120(2):440-448.10.1182/blood-2012-01-403113372160322529288
- 12. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860-3867. Blood. 2017;130(14):1684..10.1182/blood-2017-08-803171563001628983021
- 13. O’Brien KL, Price TH, Howell C, Delaney M. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura. J Clin Apher. 2013;28(6):416-421.10.1002/jca.2128823857424
- 14. Rizzo C, Rizzo S, Scirè E, et al. Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange. Blood Transfus. 2012;10(4):521-532.
- 15. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1662.10.1182/blood-2009-09-24379020032506
- 16. Grillberger R, Casina VC, Turecek PL, Zheng XL, Rottensteiner H, Scheiflinger F. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura. Haematologica. 2014;99(4):e58-e60. doi:10.3324/haematol.2013.10068510.3324/haematol.2013.100685397109624532042
- 17. Karakus V, Deveci B, Kurtoğlu E. Treatment of plasmapheresis refractory thrombotic thrombocytopenic purpura with double-filtration membrane plasmapheresis. Transfus Apher Sci. 2013;48(3):313-314.10.1016/j.transci.2013.04.00623631953
- 18. Ramadan MK, Badr DA, Hubeish M, Itani S, Hijazi H, Mogharbil A. HELLP Syndrome, Thrombotic Thrombocytopenic Purpura or Both: Appraising the Complex Association and Proposing a Stepwise Practical Plan for Differential Diagnosis. J Hematol. 2018;7(1):32-37.10.14740/jh347w715585732300409